CD274 and breast cancer: More in general, checkpoint-inhibitors have shown limited activity in metastatic BC, with the exception of atezolizumab in association with nab-paclitaxel, which in a study conferred a prolonged PFS and OS to patients with advanced triple-negative and PD-L1-positive tumors [31].